BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26353896)

  • 1. Large sample inference for a win ratio analysis of a composite outcome based on prioritized components.
    Bebu I; Lachin JM
    Biostatistics; 2016 Jan; 17(1):178-87. PubMed ID: 26353896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial.
    Kotalik A; Eaton A; Lian Q; Serrano C; Connett J; Neaton JD
    Clin Trials; 2019 Dec; 16(6):626-634. PubMed ID: 31389723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components.
    Dong G; Li D; Ballerstedt S; Vandemeulebroecke M
    Pharm Stat; 2016 Sep; 15(5):430-7. PubMed ID: 27485522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On recurrent-event win ratio.
    Mao L; Kim K; Li Y
    Stat Methods Med Res; 2022 Jun; 31(6):1120-1134. PubMed ID: 35345957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of composite time to first event versus joint marginal analyses of multiple outcomes.
    Bebu I; Lachin JM
    Stat Med; 2018 Nov; 37(27):3918-3930. PubMed ID: 29956365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of the win odds in the design of non-inferiority clinical trials.
    Peng L
    J Biopharm Stat; 2020 Sep; 30(5):941-946. PubMed ID: 32475213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The stratified win ratio.
    Dong G; Qiu J; Wang D; Vandemeulebroecke M
    J Biopharm Stat; 2018; 28(4):778-796. PubMed ID: 29172988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An alternative approach to confidence interval estimation for the win ratio statistic.
    Luo X; Tian H; Mohanty S; Tsai WY
    Biometrics; 2015 Mar; 71(1):139-145. PubMed ID: 25156540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A win ratio approach to comparing continuous non-normal outcomes in clinical trials.
    Wang D; Pocock S
    Pharm Stat; 2016 May; 15(3):238-45. PubMed ID: 26970432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the Wei-Lachin multivariate one-directional test to multiple event-time outcomes.
    Lachin JM; Bebu I
    Clin Trials; 2015 Dec; 12(6):627-33. PubMed ID: 26336199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size formula for general win ratio analysis.
    Mao L; Kim K; Miao X
    Biometrics; 2022 Sep; 78(3):1257-1268. PubMed ID: 34047366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weighted win loss approach for analyzing prioritized outcomes.
    Luo X; Qiu J; Bai S; Tian H
    Stat Med; 2017 Jul; 36(15):2452-2465. PubMed ID: 28343373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the global statistical test and composite outcome for secondary analyses of multiple coronary heart disease outcomes.
    Baraniuk S; Seay R; Sinha AK; Piller LB
    Prog Cardiovasc Dis; 2012; 54(4):357-61. PubMed ID: 22226004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The win odds: statistical inference and regression.
    Song J; Verbeeck J; Huang B; Hoaglin DC; Gamalo-Siebers M; Seifu Y; Wang D; Cooner F; Dong G
    J Biopharm Stat; 2023 Mar; 33(2):140-150. PubMed ID: 35946932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust statistical inference for matched win statistics.
    Matsouaka RA
    Stat Methods Med Res; 2022 Aug; 31(8):1423-1438. PubMed ID: 35578578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunities and challenges of combined effect measures based on prioritized outcomes.
    Rauch G; Jahn-Eimermacher A; Brannath W; Kieser M
    Stat Med; 2014 Mar; 33(7):1104-20. PubMed ID: 24122841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of composite outcomes to assess risk-benefit in clinical trials.
    Shaw PA
    Clin Trials; 2018 Aug; 15(4):352-358. PubMed ID: 30021496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.
    Pocock SJ; Ariti CA; Collier TJ; Wang D
    Eur Heart J; 2012 Jan; 33(2):176-82. PubMed ID: 21900289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A class of proportional win-fractions regression models for composite outcomes.
    Mao L; Wang T
    Biometrics; 2021 Dec; 77(4):1265-1275. PubMed ID: 32974905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graphing the Win Ratio and its components over time.
    Finkelstein DM; Schoenfeld DA
    Stat Med; 2019 Jan; 38(1):53-61. PubMed ID: 30206956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.